Cargando…
Adenosine signaling: Optimal target for gastric cancer immunotherapy
Gastric cancer (GC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Due to asymptomatic or only nonspecific early symptoms, GC patients are usually in the advanced stage at first diagnosis and miss the best opportunity of treatment. Immunotherapies, especia...
Autores principales: | Wang, Junqing, Du, Linyong, Chen, Xiangjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523428/ https://www.ncbi.nlm.nih.gov/pubmed/36189223 http://dx.doi.org/10.3389/fimmu.2022.1027838 |
Ejemplares similares
-
Oncolytic virus: A catalyst for the treatment of gastric cancer
por: Wang, Junqing, et al.
Publicado: (2022) -
Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022) -
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
por: Vigano, Selena, et al.
Publicado: (2019) -
Editorial: Adenosine pathways in cancer immunity and immunotherapy
por: Fu, Junjiang, et al.
Publicado: (2023) -
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy
por: Sun, Changfa, et al.
Publicado: (2022)